StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The significant increase in price target suggests high growth expectations for PRAX. A similar instance occurred when price expectations correlated with successful drug trials, leading to price surges.
What happened, with direct paths to the underlying reporting
BTIG raised PRAX price target from $507 to $843. PRAX shares closed at $268.95 on Friday. Analyst Kambiz Yazdi maintained a Buy rating for PRAX.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.